Prime Medicine, Inc. (PRME)
4.45
-0.52
(-10.46%)
USD |
NASDAQ |
Nov 05, 16:00
4.49
+0.04
(+0.90%)
After-Hours: 06:41
Prime Medicine SG&A Expense (TTM) : 54.39M for June 30, 2026
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 54.39M |
| March 31, 2026 | 56.47M |
| December 31, 2025 | 52.35M |
| September 30, 2025 | 49.91M |
| June 30, 2025 | 52.80M |
| March 31, 2025 | 52.29M |
| December 31, 2024 | 50.16M |
| September 30, 2024 | 50.94M |
| June 30, 2024 | 47.34M |
| March 31, 2024 | 45.39M |
| December 31, 2023 | 43.39M |
| September 30, 2023 | 39.93M |
| Date | Value |
|---|---|
| June 30, 2023 | 36.04M |
| March 31, 2023 | 32.75M |
| December 31, 2022 | 29.82M |
| September 30, 2022 | 27.38M |
| June 30, 2022 | 23.80M |
| March 31, 2022 | 18.76M |
| December 31, 2021 | 13.92M |
| September 30, 2021 | 8.075M |
| June 30, 2021 | 5.048M |
| March 31, 2021 | 2.727M |
| December 31, 2020 | 1.338M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Intellia Therapeutics, Inc. | 105.74M |
| Beam Therapeutics, Inc. | 98.66M |
| Twist Bioscience Corp. | 290.29M |
| Moderna, Inc. | 965.00M |
| Q32 Bio, Inc. | 13.91M |